New therapeutic options for HCV infection in the monoclonal antibody era

Giuseppe Andrea Sautto, Roberta Antonia Diotti, Massimo Clementi

Research output: Contribution to journalArticlepeer-review


Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease and the most common indication for liver transplantation. Current therapies are ineffective in a relevant percentage of patients raising the urgent medical need to develop adequate therapies for this infection. Broadly neutralizing human monoclonal antibodies (mAbs) directed against the HCV E2 glycoprotein (HCV/E2), the major target of the neutralizing humoral immune response, are considered as a possible novel therapeutic strategy for this infection. In the last few years, several anti-HCV/E2 human mAbs have been described in literature to be possibly used for therapeutic or prophylactic purposes. In this review, we illustrate the best candidates for an anti-HCV mAb-based therapy, considering their cross-neutralization profiles and their ability to overcome possible viral escape mechanisms.

Original languageEnglish
Pages (from-to)387-397
Number of pages11
JournalNew Microbiologica
Issue number4
Publication statusPublished - 2012


  • Anti-HCV/E2 mAbs
  • Hcv
  • MAbs
  • Viral escape

ASJC Scopus subject areas

  • Microbiology (medical)


Dive into the research topics of 'New therapeutic options for HCV infection in the monoclonal antibody era'. Together they form a unique fingerprint.

Cite this